Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Efforts Accelerate To Add Unique Device IDs To Insurance Claims

This article was originally published in The Gray Sheet

Executive Summary

Groups are mobilizing now to ensure that UDIs for high risk implantable devices are incorporated into claims, although it will likely be several years at least before that becomes a reality. The goal is to facilitate better data collection and more effective product recalls.

You may also be interested in...



Medicare Agency Comes On Board With Adding UDIs To Claims Forms

The acting head of the Center for Medicare and Medicaid Services has signaled his agency's plan to support the effort to get UDIs incorporated as a standard element of insurance claims by signing a letter jointly with the FDA commissioner. Previously, CMS had worried about the move due to the significant system upgrades that hospitals and payers will need to make to support UDIs in claims.

Questions Remain On Incorporating UDIs Into Health Care System

As part of implementation of unique device identifier requirements, hospitals will need to capture the unique codes in electronic health records and claims forms, but the logistics of doing so are still being worked out.

UnitedHealthcare Teams Up With Hospitals To Scrutinize Device Outcomes

The joint venture, SharedClarity, is focused on identifying the best-performing devices in a range of categories to inform purchasing efforts by participating hospitals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel